Invivyd (IVVD) Other Non-Current Liabilities (2021 - 2023)
Invivyd's (IVVD) quarterly Other Non-Current Liabilities came in at $700000.0 in Q4 2023, little changed quarter-over-quarter from $700000.0 in Q3 2023.
Powered by 
Analysis
Invivyd (IVVD) Other Non-Current Liabilities (2021 - 2023) Analysis & Trends
Invivyd (IVVD) has reported Other Non-Current Liabilities for 2 consecutive years, with $700000.0 the latest figure, recorded in Q4 2023.
- For the quarter ending Q4 2023, Other Non-Current Liabilities changed N/A year-over-year to $700000.0; the trailing twelve-month figure through Dec 2023 stood at $700000.0 (changed N/A YoY), and the FY2023 full-year result was $700000.0, changed N/A from the prior year.
- Other Non-Current Liabilities steadied at $700000.0 in Q4 2023 per IVVD's latest filing, from $700000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $700000.0 in Q3 2023 and bottomed at $6000.0 in Q4 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | Invivyd | 244.65 Mn | 84.57 Mn | 13.01 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 700,000.00 |
| Sep 30, 2023 | 700,000.00 |
| Dec 31, 2021 | 6,000.00 |